MaxiK, c-Src and vasoconstriction.
Toro
L
L
Department of Anesthesiology, Division of Molecular Medicine, University of California, Los Angeles, 90095, USA.
Alioua
A
A
Mahajan
A
A
Nishimaru
K
K
Zarei
M M
MM
Stefani
E
E
D000081247:CSK Tyrosine-Protein Kinase; D002460:Cell Line; D006801:Humans; D051037:Large-Conductance Calcium-Activated Potassium Channel alpha Subunits; D051036:Large-Conductance Calcium-Activated Potassium Channels; D008958:Models, Molecular; D009131:Muscle, Smooth, Vascular / Q000187:drug effects / Q000502:physiology; D010455:Peptides / Q000494:pharmacology; D024681:Potassium Channels, Calcium-Activated / Q000037:antagonists & inhibitors / Q000502:physiology*; D011505:Protein-Tyrosine Kinases / Q000502:physiology*; D014661:Vasoconstriction / Q000502:physiology*; D014662:Vasoconstrictor Agents / Q000378:metabolism*; D019061:src-Family Kinases
C494841:KCNMA1 protein, human; D051037:Large-Conductance Calcium-Activated Potassium Channel alpha Subunits; D051036:Large-Conductance Calcium-Activated Potassium Channels; D010455:Peptides; D024681:Potassium Channels, Calcium-Activated; D014662:Vasoconstrictor Agents; C064719:iberiotoxin; D011505:Protein-Tyrosine Kinases; D000081247:CSK Tyrosine-Protein Kinase; D019061:src-Family Kinases; C000631346:CSK protein, human